Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Health Monitor Liechtenstein.
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...
Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy
LONDON, UNITED KINGDOM, June 9, 2025 /EINPresswire.com/ -- The Principality of Liechtenstein continues to demonstrate its exceptional standing on the global stage, with two recent developments underscoring its strength in both financial...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*)...
4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion
Press Release 4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone payments...
Working Visit of His Serene Highness Hereditary Prince Alois Philipp Maria of the Principality of Liechtenstein to Singapore, 1 to 4 November 2024
His Serene Highness Hereditary Prince Alois Philipp Maria of the Principality of Liechtenstein will make a working visit to Singapore from 1 November to 4 November 2024. During the visit, HSH Hereditary Prince Alois will meet President Tharman...
Owner: Singaporean Government
Increasing Oral Healthcare Awareness to Propel Dental Equipment Market Growth at USD 10.90 Billion by 2031 |SkyQuest Technology
Westford, USA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dental Equipment Market size was valued at USD 6.79 billion in 2023 to USD 10.90 billion by 2031, growing at a CAGR of 6.10% during the forecast period (2024-2031). The tools that are utilized for...
Steam Boiler Systems Market USD 16.86 Billion in 2024 – Growth, Trends & Regional Insights
Steam Boiler Systems Market was valued at USD 16.86B in 2024, with Asia-Pacific leading at 40%+ installations, driven by energy efficiency & smart tech growth. WILMINGTON, DE, UNITED STATES, September 30, 2025 /EINPresswire.com/ -- The Steam...
SEALSQ and Kaynes SemiCon Announce Joint Venture to Establish India's First Secure Semiconductor Center for Onshore Personalization and Quantum-Resistant Technology
Geneva, Switzerland / India, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products,,...
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra reduced...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing...
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First...
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older who are able to walk The...
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28,...
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing...
Veterinary Pain Management Market Growth, Opportunities, Industry Applications, Analysis and Forecast by 2032
Veterinary Pain Management Market Was valued at USD 2.2 Bn. in 2024 is expected to grow at CAGR 6.5 % from 2025 to 2032 Reaching nearly 3.64 Bn. by 2032 SAN DIEGO, CA, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Stellar Market Research...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission...
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal...
Dental Implants Market worth US$18.79 billion by 2030 with 8.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 19, 2025 (GLOBE NEWSWIRE) -- The global dental implants market, valued at US$11.61 billion in 2024, stood at US$12.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in...